| __timestamp | Celldex Therapeutics, Inc. | PTC Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20622000 | 44820000 |
| Thursday, January 1, 2015 | 33837000 | 82080000 |
| Friday, January 1, 2016 | 35979000 | 97130000 |
| Sunday, January 1, 2017 | 25003000 | 121271000 |
| Monday, January 1, 2018 | 19269000 | 153548000 |
| Tuesday, January 1, 2019 | 15426000 | 202541000 |
| Wednesday, January 1, 2020 | 14456000 | 245164000 |
| Friday, January 1, 2021 | 20488000 | 285773000 |
| Saturday, January 1, 2022 | 27195000 | 325998000 |
| Sunday, January 1, 2023 | 30914000 | 332540000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for financial health. Over the past decade, PTC Therapeutics, Inc. and Celldex Therapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, PTC Therapeutics saw a staggering 642% increase in SG&A expenses, peaking at $332 million in 2023. In contrast, Celldex Therapeutics maintained a more conservative growth of 50%, with expenses reaching $31 million in the same year.
This divergence highlights PTC's aggressive expansion strategy, while Celldex appears to focus on cost containment. The data suggests that PTC's approach may be linked to broader market ambitions, whereas Celldex's strategy could be aimed at maintaining operational efficiency. As investors and industry watchers analyze these trends, the question remains: which strategy will yield better long-term returns?
AbbVie Inc. vs PTC Therapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Sanofi and Celldex Therapeutics, Inc.
Who Optimizes SG&A Costs Better? GSK plc or Celldex Therapeutics, Inc.
Summit Therapeutics Inc. and Celldex Therapeutics, Inc.: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Pharming Group N.V. and PTC Therapeutics, Inc.
Comparing SG&A Expenses: Viking Therapeutics, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Celldex Therapeutics, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Vericel Corporation
Who Optimizes SG&A Costs Better? PTC Therapeutics, Inc. or HUTCHMED (China) Limited
Veracyte, Inc. or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Catalyst Pharmaceuticals, Inc. and Celldex Therapeutics, Inc.
ImmunityBio, Inc. vs Celldex Therapeutics, Inc.: SG&A Expense Trends